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One-Sentence Summary:  
A genetic disease–associated mutation disrupts a calcium-sensing receptor structural motif causing 
biased signaling through b-arrestin. 
 
Editor’s Summary:  
GPCR signaling biased by a salt bridge 
The calcium-sensing receptor (CaSR) is a G protein–coupled receptor (GPCR) that plays an important 
role in extracellular calcium homeostasis by stimulating intracellular calcium signaling and mitogen-
activated protein kinase (MAPK) pathways. Mutations in CASR that specifically affect either 
intracellular calcium or MAPK signaling have been associated with inherited forms of hypocalcemia. 
Gorvin et al. identified a CASR mutation that results in an Arg-to-Gly substitution at amino acid 
position 680 (R680G) in CaSR, in a family with hypocalcemia. Functional analysis of CaSRR680G in 
cultured cells revealed that this missense mutation did not affect intracellular calcium signaling but 
enhanced the ability of CaSR to stimulate MAPK through a mechanism that depended on the 
scaffolding protein b-arrestin, rather than on G proteins. 
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demonstrated that the substitution likely disrupted a salt bridge in CaSR. These findings identify a 
structural feature of CaSR that is important for controlling signaling bias. 
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ABSTRACT 
The calcium-sensing receptor (CaSR) is a G protein–coupled receptor (GPCR) that signals through 
Gq/11 and Gi/o to stimulate cytosolic calcium (Ca2+i) and mitogen-activated protein kinase (MAPK) 
signaling to control extracellular calcium homeostasis. Studies of loss- and gain-of-function CASR 
mutations, which cause familial hypocalciuric hypercalcemia type 1 (FHH1) and autosomal dominant 
hypocalcemia type 1 (ADH1), respectively, have revealed the CaSR to signal in a biased manner. 
Thus, some mutations associated with FHH1 lead to signaling predominantly through the MAPK 
pathway, whereas mutations associated with ADH1 preferentially enhance Ca2+i responses. Here, we 
report a previously unidentified ADH1-associated R680G CaSR mutation, which led to the 
identification of a CaSR structural motif that mediates biased signaling. Expressing the R680G CaSR 
mutant in HEK293 cells showed that this mutation increased MAPK signaling without altering Ca2+i 
responses. Moreover, this gain-of-function in MAPK activity occurred independently of Gq/11 and Gi/o, 
and was mediated instead by a non-canonical pathway involving β-arrestin scaffolding proteins. 
Homology modeling and mutagenesis studies showed the R680G CaSR mutation selectively 
enhanced β-arrestin signaling by disrupting a salt bridge formed between Arg680 and Glu767, which are 
located in the CaSR transmembrane domain 3 and extracellular loop-2, respectively. Thus, our results 
demonstrate CaSR signaling through β-arrestin and the importance of the Arg680-Glu767 salt bridge in 
mediating signaling bias. 
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INTRODUCTION 
 
The calcium-sensing receptor (CaSR) is a family C G protein–coupled receptor (GPCR) that is highly 
abundant in the parathyroid glands and kidneys and plays an essential role in extracellular calcium 
(Ca2+e) homeostasis by decreasing parathyroid hormone (PTH) secretion and increasing urinary 
calcium excretion in response to elevations in Ca2+e concentrations (1). The human CaSR is encoded 
by the CASR gene located on chromosome 3q21.1 and consists of: an extracellular domain, which 
binds Ca2+e and mediates receptor dimerization; seven transmembrane domains (TMDs); and an 
intracellular domain, which is involved in activation of downstream signaling effectors such as G 
proteins and phospholipase C (PLC) (2, 3). The CaSR stimulates two major signal transduction 
cascades. The first is the Gq/11-phospholipase C (PLC)-mediated generation of inositol 1,4,5-
trisphosphate (IP3), which induces a rapid rise in intracellular calcium (Ca2+i) concentrations (4). The 
second is the mitogen-activated protein kinases (MAPKs), such as extracellular signal–regulated 
kinases 1 and 2 (ERK1/2), which phosphorylate proteins mediating cytosolic signaling and translocate 
into the nucleus to activate transcription factors involved in cellular proliferation and differentiation 
(5). The CaSR has been shown to activate MAPK signaling in a manner that depends on the G 
proteins Gq/11, and Gi/o, which inhibits cyclic adenosine monophosphate (cAMP) synthesis, and by a 
potentially G protein–independent mechanism involving β-arrestin types 1 and 2 (6). β-arrestins are 
intracellular scaffolding proteins that play a critical role in inactivating GPCRs by inhibiting 
interactions with G proteins and by targeting these receptors for clathrin-mediated endocytosis (7). 
Moreover, β-arrestins have been shown to enhance GPCR-mediated MAPK signaling from clathrin-
coated structures (8).  
 
The importance of the CaSR in the regulation of Ca2+e has been highlighted by the identification of 
loss-of-function CaSR mutations that give rise to familial hypocalciuric hypercalcemia type 1 (FHH1) 
and neonatal severe hyperparathyroidism (NSHPT), as well as by gain-of-function CaSR mutations 
that cause autosomal dominant hypocalcemia type 1 (ADH1), which is characterized by 
hypocalcemia, hyperphosphatemia, normal or low circulating PTH concentrations, ectopic 
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calcifications, and a relative or absolute hypercalciuria (9, 10). Functional studies have demonstrated 
that these disease-causing mutations may influence the signaling responses of CaSR-expressing cells 
in a biased manner (11). Thus, some FHH1-causing mutations switch the CaSR from preferentially 
coupling to Ca2+i to signaling equally through the Ca2+i and MAPK pathways or predominantly 
through MAPK (11). In contrast, many ADH1-associated CaSR mutations lead to a signaling bias by 
causing CaSR to couple more strongly to Ca2+i (11) than to MAPK pathways. Studies involving 
positive and negative allosteric CaSR-modulating compounds, known as calcimimetics and 
calcilytics, respectively, have also revealed biased signaling responses, with both classes of drugs 
influencing Ca2+i to a greater extent than they do ERK1/2 phosphorylation (12). Although these 
findings have established that agonist-induced CaSR signaling may occur in a biased manner, the 
GPCR structural motifs that mediate ligand-dependent bias remain to be elucidated. Here, we describe 
a previously unidentified ADH1-causing mutation that affects the Arg680 residue of CaSR, which is 
located at the outer membrane end of TMD3. Our studies show that this residue is involved in 
forming a salt bridge with the extracellular loop 2 (ECL2) residue Glu767. This salt bridge influences 
β-arrestin signaling, and its disruption leads to enhanced MAPK signaling without altering Ca2+i 
responses. 
 
 
 
 
 
  
6 
 
RESULTS 
A CaSRR680G mutation is responsible for autosomal dominant hypocalcemia type 1 (ADH1) in a 
family 
The proband, a 7-year-old male, presented with hypocalcemic symptoms (Table S1). The 
hypocalcemia was associated with a low serum PTH concentration. His father also had hypocalcemia, 
whereas his mother and two paternal half-siblings were normocalcemic (Fig. 1A, Table S1). DNA 
sequence analysis of CASR in the proband and his father (Fig. 1A) identified a heterozygous C-to-G 
transition at nucleotide c.2038 (Fig. 1B), which resulted in a missense substitution of Arg680 to Gly 
(R680G) (Fig. 1C) that is located in TMD3 of the CaSR protein (Fig. 1D). Bioinformatic analyses 
using the Polyphen-2 and MutationTasting websites (13, 14) predicted the R680G mutation to be 
damaging and likely disease-causing (Polyphen-2 score 1, MutationTasting score 0.99). The absence 
of this DNA sequence abnormality in >6500 exomes from the National Heart, Lung and Blood 
Institute Exome Sequencing Project (NHLBI-ESP) cohort and >60,700 exomes from the Exome 
Aggregation Consortium (ExAC) cohort, together with evolutionary conservation of the Arg680 
residue in the CaSR (Fig. 1D), also indicated that R680G likely represents a pathogenic mutation 
rather than a benign polymorphic variant. Furthermore, mutations involving this residue have been 
reported in two cases of FHH, in which Arg680 was mutated to either a Cys or His residue, indicating 
that the Arg680 residue is important in CaSR function (11, 15). We therefore characterized the effects 
of the R680G missense mutation in vitro to determine its effect on CaSR-mediated signaling.   
 
CaSRR680G is present at the plasma membrane and does not exhibit abnormal intracellular 
calcium signaling 
FHH1-causing mutations at Arg680 have been reported to decrease CaSR accumulation at the cell 
surface (11). We therefore evaluated whether the ADH1-causing R680G mutation may also affect the 
abundance of CaSR at the plasma membrane. Western blot analyses, using cytoplasmic and plasma 
membrane fractions of HEK293 cells transiently transfected with plasmid constructs that expressed 
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either the wild-type (CaSRWT) or mutant (CaSRR680G) CaSR fused to the N-terminus of enhanced GFP 
(pEGFP-N1) (16, 17), revealed both CaSRWT and CaSRR680G to be present at the cell surface (fig. 
S1A-S1D). Furthermore, quantification of the abundance of CaSRWT and CaSRR680G at the plasma 
membrane by Western blot analyses of cells that transiently expressed each protein and were 
biotinylated using the membrane-impermeant sulfo-NHS-SS-biotin, revealed that the abundance of 
CaSRWT and CaSRR680G at the cell surface was not significantly different (fig. S1, S2A-S2C). Thus, 
unlike the FHH-causing mutations at Arg680, the R680G mutation did not alter the abundance of the 
CaSR at the plasma membrane. 
To assess the effects of the R680G mutation on CaSR-mediated Ca2+i responses, we transiently 
transfected HEK293 cells with pEGFP-N1-CASR constructs that expressed EGFP-tagged versions of  
CaSRWT , CaSRR680G, or the previously characterized ADH1-causing L173F mutant CaSR (CaSRL173F) 
(16). Expression of CaSRs was confirmed by Western blot analysis (Fig. 2A). The Ca2+i responses in 
cells expressing wild-type or mutant CaSRs, as measured by a Fluo-4 intracellular calcium assay (18), 
increased in a dose-dependent manner in response to stimulation with increasing Ca2+e concentrations 
([Ca2+]e) of 0-15mM (Fig. 2, B and C), as expected. Expression of CaSRL173F resulted in a leftward 
shift of the concentration-response curve (Fig. 2B), with a significantly lower half maximal (EC50) 
value, compared to expression of CaSRWT (Fig. 2, B and C), whereas the EC50 value for cells 
expressing CaSRR680G was not significantly different from cells expressing CaSRWT. Thus, the EC50 
for cells expressing CaSRWT was 2.64mM (95% confidence interval (CI) = 2.40-2.89mM), compared 
to 1.68mM (95%CI = 1.50-1.89mM) for CaSRL173F-expressing cells, and 2.73mM (95%CI = 2.56-
2.90mM) for CaSRR680G -expressing cells (Fig. 2, B and C). Therefore, the R680G mutation did not 
affect Ca2+i signaling downstream of CaSR. Previous studies have demonstrated that the Arg680 
residue lies within the binding pocket for the calcilytic compound NPS-2143 (18). To investigate 
whether the R680G mutation may disrupt NPS-2143–mediated allosteric inhibition of the CaSR, we 
measured the Ca2+i responses of cells expressing the L173F or R680G mutant forms of CaSR in the 
presence of 500nM NPS-2143, a concentration 25 times greater than that required to normalize a 
reported gain-of-function CaSR mutation (19). Treatment with 500nM NPS-2143 significantly 
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increased the EC50 of CaSRWT-expressing cells to 3.81mM (95% CI = 3.56-4.08mM) compared to 
untreated CaSRWT-expressing cells and that of CaSRL173F-expressing cells to 3.34mM (95% CI = 3.12-
3.57mM) compared to untreated CaSRL173F-expressing cells (Fig. 2, B and C). In contrast, this 
concentration of NPS-2143 had no significant effect on the EC50 values of cells expressing CaSRR680G 
(Fig. 2, B and C). Thus, the R680G mutation abrogated the effect of NPS-2143 on CaSR-mediated 
Ca2+i responses. 
To verify the findings of the Ca2+i Fluo-4 assays, we performed luciferase reporter assays using a 
construct containing a nuclear factor of activated T-cells (NFAT) response element, which is activated 
by increases in Ca2+i (20). We measured NFAT luciferase reporter activity in HEK293 cells 
transiently co-transfected with the reporter construct and CaSRWT , CaSRR680G or CaSRL173F. Western 
blot analysis confirmed the expression of wild-type and mutant CaSRs in these cells (Fig. 2D), and 
the NFAT reporter activity increased in a dose-dependent manner following stimulation with 
increasing [Ca2+]e (Fig. 2E). Cells expressing CaSRL173F showed significantly increased NFAT fold-
change responses (fold-change = 13.8 ± 1.1 following exposure to 5mM [Ca2+]e), compared to cells 
expressing CaSRWT (fold-change = 6.1 ± 0.7, Fig. 2E). In contrast, CaSRR680G-expressing cells had 
similar NFAT reporter activity (fold-change = 8.7 ± 1.7) to that of cells expressing CaSRWT (Fig. 2E).  
 
The R680G mutation increases MAPK signaling downstream of CaSR 
To assess whether the R680G CaSR mutation may influence MAPK signaling, we measured fold-
changes in phosphorylated ERK1/2 in response to increasing [Ca2+]e in HEK293 cells transiently 
expressing  CaSRWT, CaSRR680G, or CaSRL173F. Densitometric analysis of Western blots revealed that 
stimulation with 5mM [Ca2+]e, when compared to 0mM [Ca2+]e, increased ERK1/2 phosphorylation 
responses of cells expressing wild-type and mutant CaSRs (Fig. 3A and 3B and fig. S3A-S3D), but 
ERK1/2 phosphorylation was significantly greater in cells expressing the mutant forms of CaSR 
compared to cells expressing the wild-type CaSR. To further assess these responses, we measured 
accumulation of phosphorylated ERK1/2 in response to 0-10mM [Ca2+]e using AlphaScreen analysis 
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(Fig. 3C and 3D) following Western blotting to confirm the expression of wild-type and mutant 
CaSRs in the cells (Fig. 3C). Ca2+e stimulation induced a dose-dependent increase in phosphorylated 
ERK1/2 fold-change responses in all cells (Fig. 3D). These responses were significantly increased at 
10mM [Ca2+]e, a concentration that has been reported to lead to near-maximal signaling responses in 
CaSR-expressing HEK293 cells (21), in both the CaSRR680G- and CaSRL173F-expressing cells (4.7 ± 
0.1 and 5.2 ± 0.2, respectively), compared to cells expressing CaSRWT (3.6 ± 0.1) (Fig. 3D). We also 
investigated the effect of the R680G CaSR mutation on MAPK signaling by measuring gene 
transcription induced by a luciferase reporter construct containing a serum-response element (SRE), 
which is a downstream target of ERK1/2 signaling (21, 22). Western blot analysis confirmed 
expression of wild-type and mutant CaSRs in cells used for the SRE reporter experiments (Fig. 3E), 
and exposure to Ca2+e led to a dose-dependent increase in SRE reporter activity in all cell types (Fig. 
3F). Expression of the CaSRR680G or CaSRL173F significantly increased fold-change responses at 10mM 
[Ca2+]e (R680G = 25 ± 4,; and L173F = 38 ± 8) compared to cells expressing CaSRWT (15 ± 2) (Fig. 
3F). Thus, the R680G mutation increased MAPK signaling, consistent with this being a gain-of-
function mutation (11). To determine whether the CaSRR680G may interfere with the effect of NPS-
2143 on CaSR-induced MAPK signaling, we repeated the SRE experiment in the presence of 500nM 
NPS-2143 and following stimulation with 10mM [Ca2+]e. The presence of NPS-2143 did not alter 
expression of the wild-type or mutant CaSRs (Fig. 3G) or affect the SRE reporter responses of cells 
expressing the CaSRR680G, but it reduced SRE reporter responses of cells expressing CaSRWT or 
CaSRL173F (Fig. 3H). Thus, the R680G mutation abolished the effect of NPS-2143 on CaSR-mediated 
MAPK signaling. 
 
The increased MAPK responses of CaSRR680G occur independently of Gq/11 and Gi/o 
Compared to CaSRWT, CaSRR680G exhibited increased ERK1/2 phosphorylation (Fig. 3) without 
altered Ca2+i responses (Fig. 2). To determine whether this biased signaling depended on G proteins, 
we further investigated Gq/11- and Gi/o-mediated signaling in HEK293 cells transiently transfected with  
CaSRWT, CaSRR680G, or CaSRL173F (Fig. 4A). The Gq/11 pathway was first evaluated by measuring the 
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fold-change accumulation of IP1, which is a stable metabolite of IP3 (23), in response to alterations in 
[Ca2+]e. Increasing [Ca2+]e led to a concentration-dependent fold-change increase in IP1, which was 
significantly higher in CaSRL173F-expressing cells (68 ± 8), but was not significantly different in 
CaSRR680G-expressing cells (24 ± 5), when compared to CaSRWT-expressing cells (30 ± 8) (Fig. 4B). 
The Gq/11 pathway was evaluated further by assessing the effects of two inhibitors of the Gq/11 
pathway, YM-254890 and UBO-QIC, both of which selectively block guanosine diphosphate (GDP) 
dissociation from Gq (24, 25), on SRE reporter activity in cells expressing wild-type or mutant 
CaSRs(Fig. 4C). YM-254890 abolished SRE reporter responses in CaSRWT- and  CaSRL173F-
expressing cells (Fig. 4D), but had no effect on CaSRR680G-expressing cells (Fig. 4D) when compared 
to  cells expressing CaSRWT. Similarly, UBO-QIC significantly decreased SRE reporter responses in 
CaSRWT- and CaSRL173F-expressing cells but did not significantly alter responses in CaSRR680G-
expressing cells (Fig. 4E). These findings indicated that the R680G mutation does not increase 
signaling through Gq/11 proteins.  
We assessed signaling though the Gi/o pathway by measuring cAMP accumulation in cells expressing 
the wild-type or mutant forms of CaSR (Fig. 5A) in response to increasing [Ca2+]e. A dose-dependent 
decrease in cAMP was observed in all cells (Fig. 5B), and cells expressing CaSRL173F had a more 
pronounced cAMP inhibition at 2.5mM Ca2+e and a significantly lower half maximal inhibitory 
concentration (IC50) value of 1.05mM (95%CI = 0.88-1.22), compared to cells expressing CaSRWT 
(IC50 = 3.11mM (95%CI = 2.88-3.34mM) (Fig. 5C). In contrast, the cAMP responses of cells 
expressing CaSRR680G (IC50 = 3.10mM (95%CI = 2.90-3.30)) did not significantly differ from cells 
expressing CaSRWT (Fig. 5, B-C). To confirm that the R680G mutation does not enhance MAPK 
signaling through a Gi/o-dependent pathway, we also evaluated SRE reporter activity in the presence 
of pertussis toxin (PTx), which is a selective Gi/o inhibitor. Treatment with PTx or vehicle had no 
effect on the expression of CaSRWT, CaSRR680G, or CaSRL173F (Fig. 5D). However, addition of PTx led 
to a similar (>50%) reduction in SRE reporter fold-change responses in both wild-type and mutant 
CaSR-expressing cells compared to the respective vehicle-treated cells (Fig. 5E), although PTx-
treated CaSRR680G-expressing cells continued to show significantly increased SRE reporter responses 
compared to PTx-treated cells expressing CaSRWT (Fig. 5F). Thus, inhibition of Gi/o-mediated 
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signaling does not rectify the increased SRE reporter responses caused by the R680G mutation, and 
overall the combined results indicate that the gain of function associated with the R680G mutation 
likely involves a mechanism that is independent of Gq/11 and Gi/o. 
 
The increased MAPK responses of CaSRR680G are mediated by β-arrestin 
To determine whether the increased MAPK signaling responses of cells expressing CaSRR680G may be 
mediated by a β-arrestin–dependent pathway, we performed SRE reporter assays in the presence of 
single siRNAs targeting either β-arrestin1 or β-arrestin2 or a scrambled siRNA sequence. Treatment 
of HEK293 cells transiently expressing CaSRWT, CaSRR680G, or CaSRL173F with β-arrestin1– or β-
arrestin2–targeted siRNA resulted in efficient knockdown of β-arrestin1 and β-arrestin2, respectively, 
compared to cells treated with scrambled siRNA (fig. S4A-S4B) and did not affect CaSR expression 
(Fig. 6A and 6B). In the presence of scrambled siRNA, Ca2+e-induced SRE reporter fold-change 
responses in CaSRR680G- and CaSRL173F-expressing cells were significantly increased compared to 
cells expressing CaSRWT , (Fig. 6, C to F). Treatment with β-arrestin1 or β-arrestin2 siRNA 
significantly reduced the SRE reporter activity in CaSRWT-expressing cells by 20-30% compared to 
CaSRWT-expressing cells treated with scrambled siRNA (Fig. 6C and 6D). Moreover, the knockdown 
of β-arrestin1 or β-arrestin2 in cells expressing CaSRR680G led to a marked reduction (>80%) in SRE 
reporter activity compared to the same cells treated with scrambled siRNA (Fig. 6C and 6D). 
However, the increase in SRE reporter activity of cells expressing CaSRL173F was not altered by 
knocking down β-arrestin1 or β-arrestin2 (Fig. 6E and 6F). These findings were further evaluated in 
SRE reporter studies in which cells expressing CaSRWT, CaSRR680G, or CaSRL173F were exposed to 
10mM [Ca2+]e (fig. S5A and S5B). These experiments showed that β-arrestin1 and β-arrestin2 
knockdown reduced SRE responses in cells expressing CaSRR680G, such that the SRE fold-change 
response was either decreased or not significantly different to that of cells expressing CaSRWT (fig. 
S5A and S5B). Moreover, the addition of NPS-2143 did not further reduce the SRE fold responses in 
cells expressing CaSRR680G (fig. S5A and S5B). In contrast, knocking down β-arrestin1 or β-arrestin2 
in cells expressing CaSRL173F had no effect on SRE fold-change responses when compared to 
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CaSRWT-expressing cells not treated with siRNA, whereas treatment with NPS-2143 rectified these 
SRE fold-change responses in CaSRL173F-expressing cells so that they were similar to those of cells 
expressing CaSRWT (fig. S5C and S5D). These findings confirm that the Arg680 residue is required for 
NPS-2143 to affect CaSR activity and indicate that signaling through β-arrestins does not represent a 
general mechanism for ADH1-mediated increases in MAPK responses, but does represent the 
preferred signaling pathway of CaSRR680G. 
 
The R680G mutation disrupts an Arg680-Glu767 salt bridge that is required for β-arrestin–
mediated CaSR signaling  
To determine the mechanism by which the R680G mutation, which is located in the third 
transmembrane domain (TMD3) of CaSR (Fig. 7A), may influence β-arrestin–mediated signaling, we 
constructed a homology model of the TMDs and evaluated the structural consequences of the R680G 
mutation (Fig. 7B–7D). A homology model was chosen because no crystal structure of the TMD of 
the CaSR exists. We therefore generated a homology model based on the crystal structure of the TMD 
of the related family C GPCR human metabotropic glutamate receptor 1 (mGluR1) (26), which is 
likely to have a similar structural topology to the CaSR TMD. For the homology modelling we 
utilized the mGluR1 TMD in complex with the negative allosteric modulator 4-fluoro-N-(4-(6-
isopropylamino)pyrimidin-4-yl)thiazol-2-yl)-N-methylbenzamide (FITM) (26). Arg680 of CaSR, 
which is located in the extracellular portion of TMD3, corresponds to Gln660 in TMD3 of mGluR1 
(Fig. 7C and 7D). The CaSR TMD homology model indicated that the Arg680 side chain may 
potentially form a salt bridge with the side chain of the neighbouring Glu767 residue, located in the 
extracellular loop 2 (ECL2) or, less likely, with the side chain of the more distantly sited Glu837 
residue, which is located on TMD7 (Fig. 7D). Thus, the R680G mutation likely disrupts a salt bridge 
between the Arg680 and Glu767 residues, or possibly a salt bridge between the Arg680 and Glu837 
residues. CaSR mutations of both the Glu767 and Glu837 residues have previously been shown to 
increase signaling by the CaSR (26-29), and we therefore postulated that the β-arrestin–mediated 
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increase in MAPK signaling caused by the R680G mutation may result from the disruption of a salt 
bridge between Arg680 and either Glu767 or Glu837.  
To test this hypothesis we mutated the Glu767 and Glu837 residues to Arg (E767R and E837R, 
respectively), because this would allow us to determine whether reversing the residue charge, which 
would cause a switch from a favorable salt bridge to unfavourable electrostatic interaction with 
Arg680, would affect β-arrestin–mediated CaSR signaling. The effect of the E767R and E837R 
mutations on MAPK signaling downstream of CaSR was initially assessed by Western blot analysis 
of ERK1/2 phosphorylation in response to treatment of cells with 0mM and 5mM Ca2+e. The 
abundance of phosphorylated ERK1/2 in response to 5mM Ca2+e was similar in cells expressing 
CaSRWT and CaSRE837R (fig. S6A-S6D and fig. S7A-S7D). However, cells expressing CaSRE767R had 
significantly more ERK1/2 phosphorylation compared to cells expressing CaSRWT, consistent with a 
gain of function (fig. S6 and fig. S7). These findings were further evaluated in SRE reporter studies in 
cells treated with siRNAs targeting β-arrestins. Expression of the CaSRs was confirmed by Western 
blot analysis (Fig. 8A and 8B). In the presence of scrambled siRNA, Ca2+e-induced SRE reporter 
activity in cells expressing CaSRE767R was significantly increased compared to cells expressing 
CaSRWT, whereas cells expressing CaSRE837R had SRE reporter responses similar to cells expressing 
CaSRWT (Fig. 8C and 8D). Moreover, treatment with siRNAs targeting β-arrestin1 or β-arrestin2 had 
no effect on SRE responses in cells expressing CaSRE837R (Fig. 8C and 8D) or CaSRWT, except when 
the cells were treated with 10mM Ca2+e. These results indicate that Glu837 is unlikely to be involved in 
forming a salt bridge with Arg680 or other adjacent residues (fig. S8A-S8B), and that mutations of 
Glu837 are likely to alter CaSR function by another mechanism.   
In contrast, SRE reporter activity decreased significantly upon knockdown of β-arrestin1 or β-
arrestin2 in cells expressing CaSRE767R in the presence of 2.5-10mM Ca2+e, compared to the same cells 
treated with scrambled siRNA (Fig. 8C and 8D). These findings indicate that, similar to the R680G 
mutation, the E767R mutation significantly increased CaSR-induced MAPK signaling through a β-
arrestin–mediated pathway and that Glu767 was likely required to form a salt bridge with Arg680. To 
confirm that the Arg680-Glu767 salt bridge was required for MAPK signaling, we generated a double-
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mutant CaSR, in which the Arg680 residue was mutated to Glu680 (R680E) and the Glu767 (E767R) 
residue was mutated to Arg767 (E767R). This Glu680-Arg767 double-mutant CaSR (CaSRR680E-E767R) was 
predicted to form a salt bridge between residues 680 and 767, and thus mediate MAPK signaling 
similar to CaSRWT. To determine the effect of the combined mutations on MAPK signaling, we 
initially assessed ERK1/2 phosphorylation by Western blot analysis (fig. S6 and fig. S9A-S9D), after 
confirming expression of CaSR by Western blot analysis of lysates from cells expressing wild-type 
and mutant CaSRs (Fig. 8E and 8F). The abundance of phosphorylated ERK1/2 in response to 5mM 
Ca2+e was similar in cells expressing CaSRWT and cells expressing the double mutant Glu680-Arg767 
form of CaSR (fig. S6 and fig. S9). SRE reporter responses did not differ significantly between cells 
expressing the wild-type and double mutant forms of CaSR, and knockdown of β-arrestin1 or β-
arrestin2 only reduced SRE reporter responses in the presence of 10mM Ca2+e, similarly to cells 
expressing CaSRWT (Fig. 8G and 8H). Thus, these double mutant studies demonstrated the importance 
of the salt bridge between residues 680 and 767 for CaSR-induced MAPK signaling.    
   
DISCUSSION 
Our studies have identified a previously undescribed ADH1-causing mutation affecting the CaSR 
(R680G), which causes a biased signaling response to Ca2+e and leads to a gain-of-function in MAPK 
signaling without altering Ca2+i responses (Figs. 2, 3 and 6). The effect of this mutation contrasts with 
the majority of mutations associated with ADH1, which bias the CaSR towards Ca2+i signaling (11). 
The CaSR is most abundant in the parathyroid glands (30), and the demonstration that the R680G 
CaSR mutation leads to selective MAPK activation suggests that this signaling pathway may 
influence the parathyroid set-point for PTH release. Thus, the hypocalcemia in the family harboring 
this CaSR mutation may have been caused by the MAPK pathway increasing the sensitivity of 
parathyroid cells to Ca2+e, which impaired the synthesis and release of PTH at physiological Ca2+e 
concentrations. Consistent with this, an ex-vivo study has previously shown alterations in MAPK 
activity to acutely influence PTH secretion from cultured human parathyroid cells (31). However, the 
physiological significance of CaSR-mediated biased signaling leading to MAPK activation remains to 
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be elucidated. Furthermore, our studies have revealed the importance of functionally characterizing 
CaSR variants by measuring both Ca2+i and MAPK signaling responses because the R680G mutation 
may have been mistakenly classified as a benign polymorphism if only the Ca2+i activity downstream 
of this mutant receptor had been assessed. Therefore, CaSR variants previously detected in 
hypocalcemic and hypercalcemic probands and classified as polymorphisms may require further 
evaluation to ensure that biased signaling is not a feature of these variants. 
Our studies also reveal that the Arg680 residue is critical for the binding and efficacy of the allosteric 
CaSR modulator NPS-2143. Allosteric CaSR modulators have been predicted to bind to a cavity 
formed by the extracellular portions of the CaSR TMDs (18), and it is noteworthy that the Arg680 
residue is located at the entrance to this putative binding cavity. Moreover, the NPS-2143 calcilytic 
compound is predicted to bind to this cavity, and our results showing that the CaSR R680G mutation 
abolishes NPS-2143–mediated Ca2+i and MAPK responses demonstrate the importance of the CaSR 
Arg680 residue in mediating the action of this calcilytic drug (18).  
The CaSR has previously been shown to activate the MAPK cascade through Gq/11 and Gi/o (5), and in 
keeping with this, our analysis of the reported ADH1-causing L173F CaSR mutant showed this to 
enhance MAPK signaling through Gq/11 and Gi/o (Fig. 3 to 5). Thus, two inhibitors of the Gq/11 
pathway, YM-254890 and UBO-QIC, and PTx, a selective inhibitor of Gi/o, abolished and reduced, 
respectively, the enhanced MAPK signaling associated with the L173F mutant CaSR (Fig. 4 and 5). 
In contrast, assessment of the newly identified ADH1-causing R680G mutant CaSR using the Gq/11 
and Gi/o inhibitors revealed that the associated increased MAPK signaling remained significantly 
increased compared to the MAPK signaling in similarly treated cells expressing wild-type CaSR (Fig. 
4 and 5), although it was reduced when compared to untreated cells expressing the G680 CaSR 
mutant (Fig. 4 and 5). However, the increased MAPK signaling due to the R680 mutation, but not that 
due to the F173 mutation, was significantly reduced by knockdown of β-arrestin1 or β-arrestin2 when 
compared to similarly treated cells expressing wild-type CaSR (Fig. 4 and 5).  Taken together, these 
results indicate that the gain-of-function F173 mutant CaSR signals through the canonical Gq/11 and 
Gi/o pathways, but the gain-of-function G680 mutant CaSR signals through the canonical pathways as 
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well as a non-canonical pathway that is independent of Gq/11 and Gi/o and involves the β-arrestin 
proteins (Fig. 6).  
The β-arrestins may enhance ERK1/2 signaling by acting as protein scaffolds that mediate the 
association of ERK1/2 with upstream MAPK components such as Raf-1 and the MAPK and ERK 
kinases 1 and 2 (MEK1/2) (32). The assembly of the β-arrestin–MAPK complex is triggered by 
GPCR activation and occurs after agonist-bound GPCRs have undergone clathrin-mediated 
endocytosis (33). Thus, CaSR endocytosis is likely required to mediate β-arrestin–dependent MAPK 
activation, and this is consistent with our reported finding of impaired CaSR-MAPK signaling due to 
FHH3-associated loss-of-function mutations of the adaptor-related protein 2 σ-subunit (AP2σ), which 
mediates the formation of clathrin-coated vesicles (21). Moreover, our present study has revealed that 
β-arrestins 1 and 2 mediated the gain of function caused by the R680G CaSR mutation (Fig. 6), and it 
is of note that both of these β-arrestin isoforms, which are present in parathyroid glands, have been 
reported by co-immunoprecipitation and mammalian two-hybrid assays to directly bind to the CaSR 
cytoplasmic terminus (34).  
The role of β-arrestins in GPCR endocytosis and signal transduction has been characterized (7, 32), 
although the GPCR domains and structural motifs that mediate these interactions with β-arrestins 
have not been fully elucidated. A crystal structure analysis of the GPCR family A member β2-
adrenergic receptor (β2-AR) complexed with β-arrestin 1 has shown that the GPCR cytoplasmic 
terminus, third intracellular loop, and inner membrane aspect of the TMDs facilitate β-arrestin binding 
to the GPCR (35). In addition, mutations affecting the cytoplasmic regions of family A and B GPCRs 
have been shown to selectively influence β-arrestin–mediated signaling (36, 37). Our finding that 
mutation of the CaSR Arg680 residue, which is located at the outer end of TMD3 (Fig. 7), also 
modulates β-arrestin signaling, reveals the importance of the extracellular regions of GPCRs for 
influencing β-arrestin function. Our homology modeling and functional analysis of engineered CaSR 
mutants has revealed that the Arg680 residue forms a salt bridge with the Glu767 residue located in 
ECL2 (Fig. 8) and that this salt bridge likely maintains the CaSR in an inactive conformation. Indeed, 
disruption of this salt bridge by mutating either Arg680 or Glu767 led to a gain of function in β-arrestin–
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mediated MAPK signaling, whereas restoration of the salt bridge in the Glu680-Arg767 double mutant 
normalized CaSR function (Fig. 8). The Arg680-Glu767 salt bridge therefore mediates a functionally 
important interaction between TMD3 and ECL2 (Fig. 7 and 8). ECL2 connects the outer ends of 
TMD4 and TMD5 (Fig. 7A and 7B), and thus it seems likely that disruption of the Arg680-Glu767 salt 
bridge may lead to a lateral displacement of TMD3 away from TMD4 or TMD5, thereby facilitating 
β-arrestin binding in a manner analogous to that reported in a cryo-EM structural analysis of the β2-
AR–β-arrestin complex, which showed that binding of β-arrestin to the β2-AR TMD domain core 
region is mediated by an outward shift in the positioning of the TMD3, TMD5, and TMD6 helices 
(35).  
In conclusion, we have identified a CaSR mutation (R680G) that gives rise to ADH1 by exclusively 
activating a β-arrestin–mediated MAPK signaling pathway downstream of the CaSR. These studies 
provide key insights into CaSR structure and function and indicate that a salt bridge between TMD3 
and ECL2 plays a critical role in the control of β-arrestin–mediated CaSR signaling. Moreover, 
discovery of this novel β-arrestin–specific pathway may help facilitate the development of targeted 
therapeutics that can activate CaSR-mediated β-arrestin signaling in a biased manner. 
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MATERIALS AND METHODS 
DNA sequence analysis  
Written informed consent was obtained from the individuals and their relatives, and where appropriate 
the parents and guardians of children, using protocols approved by local and national ethics 
committees. Mutational analysis of the CASR exons and adjacent splice-sites was performed as 
described (38). Publicly accessible databases (dbSNP (http://www.ncbi.nlm.nih.gov/projects/SNP/) 
(39); 1000 genomes (http://browser.1000genomes.org) (40); the National Heart, Lung and Blood 
Institute (NHLBI) Exome Sequencing Project  (http://evs.gs.washington.edu/EVS/, EVS data release 
ESP6500SI) with details from the exomes of approximately 6500 individuals; and the Exome 
Aggregation Consortium (ExAC) (exac.broadinstitute.org) with details from exomes of 60,706 
unrelated individuals (41)), were examined for the presence of the c.2038C>G sequence variant.  
 
 
Protein sequence analysis and alignment and three-dimensional modeling of the CaSR 
structure  
 The effect of the R680G mutation was predicted using Polyphen-2 
(http://genetics.bwh.harvard.edu/pph2/) (13) and MutationTasting (http://www.mutationtaster.org/) 
(14). Protein sequences of CaSR orthologs were aligned using ClustalOmega 
(http://www.ebi.ac.uk/Tools/msa/clustalo/) (42). The HHpred homology detection server 
(https://toolkit.tuebingen.mpg.de/hhpred) was used to identify proteins in the Protein Data Bank with 
structural similarity to the CaSR and to perform amino acid sequence alignment (43). The amino acid 
sequence identity between human metabotropic glutamate receptor 1 (mGluR1)(44) and the CaSR is 
28% for 282 aligned amino acid residues. The CaSR sequence was threaded onto the mGluR1 
template coordinates, and Modeller (https://toolkit.tuebingen.mpg.de/modeller) was used to construct 
a homology model (45). Figures were prepared using the PyMOL Molecular Graphics System 
(Schrodinger, LLC). 
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Cell culture, transfection, and siRNA-mediated knockdown 
Studies were performed in HEK293 cells maintained in DMEM-Glutamax media (ThermoFisher) 
with 10% fetal bovine serum (Gibco) at 37ºC, 5% CO2. Mutations were introduced into the pEGFP-
N1-CaSRWT construct by site-directed mutagenesis using the Quikchange Lightning Kit (Agilent 
Technologies) and gene-specific primers (SigmaAldrich) as described (46, 47), Engineered mutations 
were verified using dideoxynucleotide sequencing with the BigDye Terminator v3.1 cycle sequencing 
kit (Life Technologies) and an automated detection system (ABI3730 automated capillary sequencer; 
Applied Biosystems) as previously reported (48). Wild-type and mutant CaSR pEGFP-N1 constructs, 
and luciferase reporter constructs (pGL4.30-NFAT and pGL4.33-SRE, Promega) were transiently 
transfected into HEK293 cells using Lipofectamine 2000 (LifeTechnologies) 48 hours before 
experiments, as described (49). Single siRNAs targeted to β-arrestin1 (Catalog No: 6218S, Cell 
Signalling Technology) or β-arrestin2 (Catalog No: sc29208, SantaCruz Biotechnology), or scrambled 
siRNA (Catalog No: SR301839, Origene) were transfected 24 hours before experiments at a 
concentration of 100nM. Successful transfection was confirmed by Western blot analysis, with the 
calnexin housekeeping protein being used as a loading control (46). Primary antibodies recognizing 
the following proteins were used for Western blot analysis at a dilution of 1:1000: CaSR (ADD, 
ab19347, Abcam), calnexin (Ab2301, Millipore), phosphorylated ERK1/2 (9101L, Cell Signaling 
Technology), total ERK1/2 (4695S, clone 137F5, Cell Signaling Technology), plasma membrane 
calcium ATPase (PMCA1) (ab190355, Abcam), β-arrestin1 (ab175266, Abcam), and β-arrestin2 (H-
9, sc-13140, SantaCruz). The Western blots were visualized using an Immuno-Star WesternC kit 
(BioRad) on a BioRad Chemidoc XRS+ system (46). For cell fractionation studies, cells were 
transfected with CaSR constructs and 48 hours later plasma membrane and cytoplasmic fractions were 
isolated using a plasma membrane extraction kit (Catalog No 65400, Abcam), as described (50). 
Plasma membrane fractions were dissolved in 0.5% Triton-X100 in PBS, and the cytoplasmic fraction 
in the supplied homogenization buffer. Each fraction was resuspended in Laemmli buffer and Western 
blot analysis performed, as described (48). Calnexin was used as a loading control for cytoplasmic 
fractions, and the PMCA1 protein used as a loading control for plasma membrane fractions. For 
studies of phosphorylated proteins, cells were treated for 5 minutes with either 0mM or 5mM Ca2+e, 
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prior to lysis and proteins separated by SDS-PAGE. Following transfer to polyvinylidene difluoride 
(PVDF) membranes, blots were pre-incubated (blocked) in 5% bovine serum albumin (BSA) in Tris-
buffered saline with Tween-20 (TBSt) (Sigma) prior to probing for phosphorylated ERK. Blots were 
stripped with Restore Plus Western Blot Stripping Buffer (ThermoFisher) for 15 min, and then  
blocked in non-fat dried milk powder (commercially available as Marvel) dissolved in TBSt and 
reprobed for total ERK. Densitometry was performed using ImageJ 1.30 software (NIH, USA) and 
analysed using GraphPad Prism software (GraphPad software) and are expressed as mean±SEM. For 
studies involving NPS-2143 (ab145050, Abcam), cells were either incubated with DMSO (vehicle) or 
with 500 nM NPS-2143 in DMSO at 30 min prior to undertaking Fluo-4 Ca2+i experiments (18), and 
for four hours prior to undertaking luciferase reporter assay experiments (49).  
 
Surface biotinylation experiments 
Biotinylation assays were performed by adapting previously published methods (51). Briefly, 
HEK293 cells were grown in T75 flasks and transiently transfected with 8 µg wild-type or mutant 
CaSR constructs. Forty-eight hours later cells were biotinylated using the membrane-impermeant 
sulfo-NHS-SS-biotin (Pierce, 2.5 mg/ml in PBS) for 30 minutes on ice. Cells were then rinsed with 
ice-cold PBS plus 100mM glycine, and solubilized in cell lysis buffer (150mM NaCl, 50mM Tris-
HCl, pH 7.4, 1mM EDTA, 1% Triton X-100) supplemented with 1 tablet of cOmplete, EDTA-free 
protease inhibitor cocktail (Roche). Cells were lysed for 1 hour at 4°C, pelleted at 13,000 x g for 15 
minutes, and biotinylated proteins isolated by incubation with streptavidin-agarose beads (Pierce) 
overnight at 4°C on a rotating wheel. Precipitates were washed with lysis buffer, and biotinylated 
proteins were eluted from beads using Laemmli buffer. Biotinylated proteins were then resolved by 
SDS-PAGE and probed for CaSR as described above. A 1:10 dilution of total protein was resolved 
alongside biotinylated proteins as a control.  Specificity of surface biotinylation was confirmed by the 
absence of the intracellular calnexin in the biotinylated fraction, but presence in total protein fractions. 
Densitometry was performed using ImageJ 1.30 software (NIH, USA) and analysed using GraphPad 
Prism software (GraphPad software) and are expressed as mean±SEM. 
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Intracellular calcium measurements 
Ca2+e-induced Ca2+i responses were measured by Fluo-4 calcium assays adapted from previously 
reported methods (18). Briefly, CaSR-expressing HEK cells were plated in poly-L-lysine–treated 
black-walled 96-well plates (Corning), and transiently transfected with 1000ng/ml pBI-CMV2-
GNA11. On the following day, cells were incubated in serum-free media for 2 hours, then loaded with 
Fluo-4 dye according to manufacturer’s instructions (Invitrogen). Cells were loaded for 40 minutes at 
37°C, then either a 20% aqueous solution of 2-hydoxypropyl-β-cyclodextrin (vehicle) or 500 nM 
NPS-2143 was added. Cells were then incubated for a further 20 minutes at 37°C (18). Baseline 
measurements were made and increasing doses of CaCl2 (0-10 mM) injected into each well using an 
automated system. Changes in Ca2+i were recorded on a PHERAstar instrument (BMG Labtech) at 
37°C with an excitation filter of 485nm and an emission filter of 520nm. The peak mean fluorescence 
ratio of the transient response after each individual stimulus was measured using MARS data analysis 
software (BMG Labtech) and expressed as a normalized response. Nonlinear regression of 
concentration-response curves was performed with GraphPad Prism using the normalized response at 
each [Ca2+]e for each separate experiment and used to determine the EC50 (i.e. [Ca2+]e required for 
50% of the maximal response). Assays were performed in 4 biological replicates for each of the 
expression constructs. Statistical analysis was performed using the F-test (52, 53).  
 
Luciferase reporter assays 
Luciferase reporter assays were undertaken to measure SRE and NFAT responses. Cells were plated 
in 24-well plates and transiently transfected with 100ng/ml of the wild-type or mutant CaSR pEGFP-
N1 constructs, 100ng/ml luciferase construct (either pGL4-NFAT or pGL4-SRE), and 10ng/ml pRL. 
At 48 hours after transfection, cells were incubated in serum-free media overnight. Cells were then 
incubated in serum-free media containing 0-10mM CaCl2 for 4 hours. For studies with pertussis toxin 
(PTx, Catalog No: P7208, Sigma), cells were pre-incubated with 10µM forskolin (MP Biomedicals) 
overnight, then 300ng/ml PTx, or ethanol-diluent vehicle (Sigma) added with 0-10 mM CaCl2 (54). 
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For studies with Gq/11 inhibitors, cells were pre-treated with 10µM YM-254890 or vehicle (DMSO) 
for 5 minutes, or with 1µM UBO-QIC or vehicle (DMSO) for 2 hours.  Cells were lysed and assays 
performed using Dual-Glo Luciferase (Promega) on a Veritas Luminometer (Promega), as previously 
described (48). Luciferase:renilla ratios are shown as fold-changes relative to responses at basal CaCl2 
concentrations (0.1mM). Area under the curve (AUC) was calculated using GraphPad Prism and 
expressed as mean±SEM.   
 
AlphaScreen assays 
AlphaScreen assays to measure phosphorylated ERK 1/2 and cAMP were performed in 48-well plates 
using cells transiently transfected with 100ng of the wild-type or mutant CaSR pEGFP-N1 constructs 
48-hours prior to performance of assays. For phosphorylated ERK 1/2 studies, cells were incubated in 
serum-free media for 12 hours prior to 5-minute treatment with 0.1-10mM CaCl2. Cells were then 
lysed in Surefire lysis buffer (Perkin Elmer), and phosphorylated ERK 1/2 and total ERK1/2 assays 
were performed as previously described (21). For the cAMP assays, cells were treated with 10µM 
forskolin for 30 minutes prior to CaCl2 treatment in stimulation buffer [1x Hanks Buffered Saline 
Solution, 0.1% BSA, 0.1% 3-isobutyl-1-methylxanthine (IBMX), 0.5mM HEPES] plus 0.1-10mM 
CaCl2. Cells were incubated for 15 minutes, then lysed in a HEPES-based solution (0.1% BSA, 0.3% 
Tween-20, 5mM HEPES, pH7.4) and incubated for 4 hours. The fluorescence signal in AlphaScreen 
assays was measured using the PHERAstar FS microplate reader (BMG Labtech) (48). Nonlinear 
regression of concentration-response curves was performed with GraphPad Prism for the 
determination of IC50 (i.e., [Ca2+]e required for 50% inhibition of the maximal response). 
 
IP1 assay 
Assays were performed in 48-well plates and cells transiently transfected with 100ng of the wild-type 
or mutant CaSR pEGFP-N1 constructs 48 hours prior to performance of assays. At 24 hours prior to 
experiments, cells were re-plated in a 384-well plate, and 12-hours later, the media was changed to 
serum-free media. IP-One homogenous time-resolved fluorescence (HTRF) assays (Cisbio, Codolet, 
France) were performed according to manufacturer’s instructions and as previously described (23). 
23 
 
Cells were incubated for 30 minutes with stimulation buffer containing a single dose of CaCl2 (0.1-
10mM), followed by lysis in the manufacturer-supplied lysis buffer. Plates were read on a 
PHERAStar FS microplate reader one hour later (BMG Labtech). 
 
Statistical analysis 
A minimum of four independent biological replicates were used for all statistical comparisons. EC50 
and IC50 values were analysed using the F-test, as reported (53). All other data was analyzed by 2-way 
ANOVA with Tukey’s multiple-comparisons test. Statistical analyses were undertaken using 
GraphPad Prism (GraphPad), and a value of p<0.05 was considered significant for all analyses.  
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SUPPLEMENTARY MATERIALS 
Fig. S1. Plasma membrane and cytoplasmic CaSR in HEK293 cells 
Fig. S2. Abundance of CaSR in plasma membrane fractions  
Fig. S3. ERK phosphorylation in the ADH1-associated R680G and L173F mutant CaSRs used for 
densitometry analysis 
Fig. S4 siRNA-mediated knockdown of β-arrestin1- and β-arrestin2 
Fig. S5. Effect of NPS-2143 on β-arrestin–mediated MAPK signaling following stimulation with 
10mM [Ca2+]e  
Fig. S6. Effect of the engineered mutants E767R and E837R CaSRs on MAPK signaling 
Fig. S7. ERK phosphorylation in engineered E767R and E837R CaSR mutants used for densitometry 
analysis 
Fig. S8. Analysis of the CaSR Glu837 residue by homology modelling using the structure of mGluR1 
Fig. S9. Western blots to assess ERK phosphorylation in the engineered Glu680-Arg767 double CaSR 
mutant used for densitometry analysis 
Table S1. Clinical and biochemical findings in the parents and proband with the R680G CaSR 
mutation 
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FIGURE LEGENDS  
Fig. 1. Identification of an R680G CaSR mutation in a family with autosomal dominant 
hypocalcemia type 1 (ADH1) 
(A) Pedigree of family with ADH1. The proband (individual II.3) is indicated by an arrow. (B) A 
heterozygous C-to-G transition at nucleotide c.2038 was identified in the proband and his father  by 
Sanger DNA sequencing and confirmed to cosegregate with hypocalcemia. (C) This C-to-G transition 
changes a CGC codon to GGC and is predicted to result in a missense amino acid substitution from 
Arg to Gly at position 680 in the CaSR protein. (D) Multiple sequence alignment of residues 
surrounding the Arg680 (R) residue encompassing extracellular loop 1 (ECL1) and transmembrane 
domain 3 (TMD3). The Arg680 (R) residue, which is evolutionarily conserved, is located within 
TMD3, and the mutant Gly680 (G) residue is shown in red. Conserved residues are shaded in gray. 
 
  
  
30 
 
Fig. 2. The CaSR R680G mutation does not affect intracellular Ca2+ signaling 
(A) Western blot analysis of HEK293 cells expressing wild-type (WT) or ADH1-associated mutant 
(R680G and L173F) CaSRs. Calnexin is a loading control. (B) Intracellular Ca2+ (Ca2+i) responses to 
changes in extracellular Ca2+ concentration ([Ca2+]e) in cells expressing the indicated wild-type or 
mutant CaSRs in the absence or presence of the allosteric CaSR inhibitor NPS-2143. Inset shows 
magnification of the curves between 2-3.5mM [Ca2+]e. Data are shown as the mean±SEM from 4-7 
transfections, and EC50 values with 95% confidence intervals (CIs) are provided (F-test). (C) 
Histogram showing EC50 values with 95% CIs for cells expressing wild-type or R680G or L173F 
mutant CaSRs in the absence or presence of NPS-2143. (D) Western blot analysis of cells expressing 
the indicated wild-type and mutant forms of CaSR and used for assessment of NFAT reporter 
responses. (E) [Ca2+]e-induced NFAT reporter responses of cells expressing wild-type or mutant 
CaSRs. Responses at each [Ca2+]e are shown as a fold-change of basal (0.1mM) [Ca2+]e responses and 
presented as mean±SEM of 4 transfections. *p<0.05, **p<0.01 ****p<0.0001 using 2-way ANOVA 
with Tukey’s multiple-comparisons tests versus cells expressing wild-type CaSR at each [Ca2+]e .  
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Fig. 3. The CaSR R680G mutation increases downstream MAPK signaling 
(A) Western blot analysis showing Ca2+e-induced phosphorylation of ERK1/2 (pERK1/2) in HEK293 
cells expressing wild-type (WT) or ADH1-associated CaSR mutants (R680G or L173F). (B) 
Densitometric analysis of Western blot data in panel A. (C) Western blot analysis showing transgenic 
expression of the indicated forms of CaSR in cells used to assess Ca2+e-induced phosphorylation of 
ERK1/2 by AlphaScreen analysis. Calnexin is a loading control. (D) Ca2+e-induced ERK1/2 
phosphorylation in CaSR-expressing cells as measured by AlphaScreen analysis, shown as the ratio of 
phosphorylated ERK1/2 (pERK) to total ERK. (E) Western blot analysis showing transgenic 
expression of the indicated forms of CaSR in cells used to assess Ca2+e-induced SRE reporter activity. 
(F) Ca2+e-induced SRE reporter activity in CaSR-expressing cells. (G) Western blot analysis showing 
transgenic expression of CaSR in cells used to assess the effects of NPS-2143 on Ca2+e-induced SRE 
responses. (H) SRE reporter activity in CaSR-expressing cells in the absence or presence of the 
allosteric CaSR inhibitor. Data shows mean±SEM values for N=4-20 independent transfections. 
**p<0.01, ***p<0.001, ****p<0.0001 for CaSRR680G versus CaSRWT; $$$p<0.001, $$$$p<0.0001 for 
CaSRL173F versus CaSRWT in panels B, D and F. §§p<0.01, §§§p<0.001 for NPS-2143-treated cells 
compared to respective untreated cells in panel H. Two-way ANOVA with Tukey’s multiple-
comparisons test. 
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Fig. 4. The CaSR R680G mutation does not affect Gq/11-mediated signaling 
(A) Western blot analysis of HEK293 cells expressing wild-type (WT) or ADH1-associated CaSR 
mutants (R680G or L173F). These cells were used for assessment of IP1 responses. Calnexin is a 
loading control. (B) Ca2+e-induced IP1 fold change in cells expressing the indicated forms of CaSR. 
(C) Western blot analysis of cells used to assess the effect of the Gαq/11 inhibitors YM-254890 (YM) 
and UBO-QIC (UBO), on SRE reporter activity. (D) [Ca2+]e-induced SRE reporter activity in cells 
expressing the indicated forms of CaSR in the presence or absence of YM. (E) [Ca2+]e-induced SRE 
reporter in cells expressing the indicated forms of CaSR in the presence or absence of UBO-QIC. 
Data shows mean±SEM for 8-12 independent transfections. *p<0.05, **p<0.01 ****p<0.0001 for 
untreated cells expressing CaSRWT versus untreated (black) or YM- or UBO-QIC–treated (blue) cells 
expressing CaSRR690G in panels D and E. $p<0.05, $$p<0.01, $$$$p<0.0001 for untreated cells 
expressing CaSRWT versus untreated (black), or YM- or UBO-QIC–treated (red) cells expressing 
CaSRL173F in panels B, D and E (2-way ANOVA with Tukey’s multiple-comparisons test).  
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Fig. 5. The CaSR R680G mutation does not affect Gi/o-mediated signaling 
(A) Western blot analysis of HEK293 cells expressing wild-type (WT) or ADH1-associated CaSR 
mutants (R680G or L173F). These cells were used for assessment of cAMP responses. Calnexin is a 
loading control. (B) Ca2+e-induced fold change in cAMP abundance in cells expressing the indicated 
forms of CaSR. (C) Histograms showing the cAMP IC50 with 95% confidence intervals for cells 
expressing the indicated forms of CaSR. (D) Western blot analysis of cells expressing the indicated 
forms of CaSR in the presence of pertussis toxin (PTx) or vehicle (Veh). These cells were used to 
assess effect of PTx on SRE reporter activity. (E) Fold change in [Ca2+]e-induced SRE reporter 
activity in cells expressing the indicated forms of CaSR in the absence or presence of PTx. (F) 
Histograms showing area under the curve (AUC) of SRE reporter responses in vehicle- or PTx-treated 
cells expressing the indicated forms of CaSR. Data shows mean±SEM for 4-12 independent 
transfections. *p<0.05, ****p<0.0001 for CaSRR680G compared to CaSRWT in panels E-F. $p<0.05, 
$$$$p<0.0001 for CaSRL173F compared to CaSRWT in panels B, C, E and F (2-way ANOVA with 
Tukey’s multiple-comparisons test).  
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Fig. 6. Increased MAPK responses in cells expressing CaSRR680G involve a G-protein–
independent, β-arrestin–dependent pathway 
(A-B) Western blot analysis of HEK293 cells expressing wild-type (WT) or ADH1-associated CaSR 
mutants (R680G or L173F) and treated with scrambled siRNA (-) or siRNAs targeting (A) β-arrestin1 
(βarr1) or (B) β-arrestin2 (βarr2). Calnexin was used as a loading control. (C-D) [Ca2+]e-induced SRE 
reporter responses in cells expressing CaSRR680G and treated with a scrambled siRNA or with siRNAs 
targeting (C) βarr1or (D) βarr2 or a scrambled siRNA. (E-F) [Ca2+]e-induced SRE reporter responses 
in cells expressing CaSRL173F and treated with siRNAs targeting βarr1 (E) or βarr2 (F) or a scrambled 
siRNA. The responses of cells treated with siRNAs targeting β-arrestin were compared to the 
respective cells treated with scrambled siRNA using a 2-way ANOVA with Tukey’s multiple-
comparisons test. $p<0.05 and $$p<0.0001 for scrambled vs siRNA for cells expressing wild-type 
(black) or R680G (blue) CaSR; *p<0.05, **p<0.01, ***p<0.001, ***p<0.0001 for scrambled siRNA 
treatment of cells expressing wild-type CaSR vs mutant CaSR (blue) and scrambled siRNA treatment 
of cells expressing wild-type CaSR vs targeted (β-arrestin) siRNA treated mutant CaSR (black). Data 
is shown as mean±SEM for 8-16 independent transfections.  
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Fig. 7. The Arg680 residue of CaSR forms a salt bridge with either Glu767 or Glu837 
(A) Schematic diagram of a CaSR monomer showing the extracellular bi-lobed venus flytrap domain 
(VFTD), seven transmembrane domains (TMDs 1-7) with extracellular loops 1–3 (ECL1–3) and 
intracellular loops 1–3 (ICL1–3), and the cytoplasmic domain. The locations of Arg680 in TMD3 
(R680, blue), Glu767 in ECL2 (E767, red), and Glu837 in TMD7 (E837, magenta) are indicated. (B) 
Ribbon diagram showing the transmembrane domains of mGluR1 derived from the published crystal 
structure (44) and a model of the CaSR transmembrane regions based on homology to mGluR1. 
TMDs 1-7 are numbered; e and i indicate the extracellular and cytoplasmic components of the plasma 
membrane, respectively. (C) Close-up view of the mGluR1 binding pocket for the negative allosteric 
modulator 4-fluoro-N-(4-(6-isopropylamino)pyrimidin-4-yl)thiazol-2-yl)-N-methylbenzamide (FITM) 
(magenta and purple molecule), and (D) the corresponding region in the CaSR. Distances between 
selected atoms are indicated with dashed lines.  
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Fig. 8. Disruption of the Arg680-Glu767 salt bridge leads to increased β-arrestin–mediated 
MAPK signaling 
(A-B) Western blot analysis of HEK293 cells expressing wild-type or engineered mutant forms of 
CaSR (E767R or E837R) and treated with siRNAs targeting (A) β-arrestin1 (βarr1) or (B) β-arrestin2 
(βarr2). (C-D) [Ca2+]e-induced SRE reporter responses in cells expressing CaSRE767R or CaSRE837R and 
treated with a scrambled siRNA or with siRNAs targeting (C) βarr1or (D) βarr2. (E-F) Western blot 
analysis of HEK293 cells expressing wild-type CaSR, E767R CaSR, or a double mutant (dm) form of 
CaSR incorporating both the R680E and E767R mutations and treated with a scrambled siRNA or 
siRNA targeting (E) βarr1 or (F) βarr2. These cells were used to assess SRE reporter activity 
following knockdown of βarr1 or βarr2. (G-H) [Ca2+]e-induced SRE reporter responses in cells 
expressing the double mutant CaSRR680E-E767R and treated with a scrambled siRNA or with siRNAs 
targeting (G) βarr1or (H) βarr2. Data shows mean±SEM for 8-16 independent transfections. *p<0.05, 
**p<0.001, ****p<0.0001 for E767R versus WT CaSR in panels C-D; $p<0.05, $$p<0.01, 
$$$$p<0.0001 for targeted versus scrambled siRNAs for wild-type (black) or E767R (blue) CaSR in 
panels C-D; $$p<0.01, $$$p<0.001, $$$$p<0.0001 for a comparison between Glu680-Arg767 or wild-type 
CaSR-expressing cells treated with targeted siRNA and respective cells treated with scrambled siRNA 
in panels G-H (2-way ANOVA with Tukey’s multiple-comparisons).  
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